Merhawit Ghebrehiwet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Merhawit Ghebrehiwet has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
3 shared publications - Andrew Wilson
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
2 shared publications - Josh Autaubo
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
2 shared publications - Katherine Cox
Office of Medical Student Research (MG, KC, DN, BD, SMJ, RB, MV); and Department of Psychiatry and Behavioral Sciences (MV), Oklahoma State University Center for Health Sciences, Tulsa
2 shared publications Matt Vassar
Office of Medical Student Research (MG, KC, DN, BD, SMJ, RB, MV); and Department of Psychiatry and Behavioral Sciences (MV), Oklahoma State University Center for Health Sciences, Tulsa
2 shared publications- Payton Clark
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Examining Recruitment and Retention Strategies in Hidradenitis Suppurativa Clinical Trials: A Cross‐Sectional Study
Background: To ensure equitable and successful treatment outcomes for hidradenitis suppurativa (HS), the recruitment and retention of diverse participants in clinical trials is critical. However, current approaches may neglect under‐represented populations, potentially limiting the result application. Objective: This study aimed to evaluate existing recruitment and retention strategies in HS trials, identifying gaps and proposing methods to improve inclusivity and participant retention. Methods: We conducted a cross‐sectional analysis of 36 HS clinical trials from January 2018 to December 2023, following PRISMA guidelines. Trial characteristics and specific recruitment/retention approaches were assessed through data extraction and Stata 18 SE statistical analysis. Results: Of the 36 trials, 18/36 (50.0%) reported use of specific retention strategies, while 1/36 (2.8%) of the trials documented recruitment strategies for under‐represented groups. Diversity goals were also unreported in recruitment processes. Most trials (63.9%) received industry funding, and therapeutic intervention was the most common treatment type (97.2%). Limitations: Only articles from 2018 to 2023 were analyzed, limiting the finding generalizability over broader timeframes. Conclusion: This study reveals significant gaps in recruitment/retention strategies within HS trials, which is important for enhancing result relevance and inclusivity, particularly among historically marginalized populations. Implementing specific approaches and innovative methods is critical for improving HS treatment efficacy and reducing health inequities.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessExamining Recruitment and Retention Strategies in Hidradenitis Suppurativa Clinical Trials: A Cross‐Sectional Study
Background: To ensure equitable and successful treatment outcomes for hidradenitis suppurativa (HS), the recruitment and retention of diverse participants in clinical trials is critical. However, current approaches may neglect under‐represented populations, potentially limiting the result application. Objective: This study aimed to evaluate existing recruitment and retention strategies in HS trials, identifying gaps and proposing methods to improve inclusivity and participant retention. Methods: We conducted a cross‐sectional analysis of 36 HS clinical trials from January 2018 to December 2023, following PRISMA guidelines. Trial characteristics and specific recruitment/retention approaches were assessed through data extraction and Stata 18 SE statistical analysis. Results: Of the 36 trials, 18/36 (50.0%) reported use of specific retention strategies, while 1/36 (2.8%) of the trials documented recruitment strategies for under‐represented groups. Diversity goals were also unreported in recruitment processes. Most trials (63.9%) received industry funding, and therapeutic intervention was the most common treatment type (97.2%). Limitations: Only articles from 2018 to 2023 were analyzed, limiting the finding generalizability over broader timeframes. Conclusion: This study reveals significant gaps in recruitment/retention strategies within HS trials, which is important for enhancing result relevance and inclusivity, particularly among historically marginalized populations. Implementing specific approaches and innovative methods is critical for improving HS treatment efficacy and reducing health inequities.
- Open Access
- 26 November 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 1-9
Recruitment and Retention Strategies for Historically Marginalized Populations in Colorectal Cancer Trials: A Cross-Sectional Analysis Using Systematic Review Methods
Purpose Colorectal cancer (CRC), a leading cause of cancer mortality, disproportionately impacts historically marginalized populations due to persistent health inequities. Effective recruitment and retention strategies are crucial to improving the representation of these populations in clinical trials. This study aims to evaluate the use of recruitment and retention strategies in CRC clinical trials, their impact on participant diversity, and the presence of diversity recruitment goals and ethical considerations. Methods We conducted a cross-sectional analysis of CRC treatment trials following PRISMA guidelines. Eligible studies were assessed for recruitment and retention strategies, diversity recruitment goals, and ethical considerations. Data were extracted in duplicate, ensuring masked and independent evaluations. Results Of the 2563 records identified, 55 studies met the inclusion criteria. Most trials (83.6%) focused on therapeutic interventions, and government funding was the most common (38.2%). Only three studies (5.5%) reported strategies to recruit historically marginalized populations, and 54 studies (98.2%) lacked diversity recruitment goals. None of the trials discussed ethical considerations related to diverse recruitment. Conclusion This study highlights significant gaps in recruitment and retention strategies for historically marginalized populations in CRC clinical trials. Few studies implement strategies to address these disparities which affect the diversity of the trial population, underscoring the need for targeted efforts to improve trial inclusivity. Addressing these gaps is critical to ensuring more equitable and representative outcomes in CRC research.
- 26 November 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 1-9
Open AccessRecruitment and Retention Strategies for Historically Marginalized Populations in Colorectal Cancer Trials: A Cross-Sectional Analysis Using Systematic Review Methods
Purpose Colorectal cancer (CRC), a leading cause of cancer mortality, disproportionately impacts historically marginalized populations due to persistent health inequities. Effective recruitment and retention strategies are crucial to improving the representation of these populations in clinical trials. This study aims to evaluate the use of recruitment and retention strategies in CRC clinical trials, their impact on participant diversity, and the presence of diversity recruitment goals and ethical considerations. Methods We conducted a cross-sectional analysis of CRC treatment trials following PRISMA guidelines. Eligible studies were assessed for recruitment and retention strategies, diversity recruitment goals, and ethical considerations. Data were extracted in duplicate, ensuring masked and independent evaluations. Results Of the 2563 records identified, 55 studies met the inclusion criteria. Most trials (83.6%) focused on therapeutic interventions, and government funding was the most common (38.2%). Only three studies (5.5%) reported strategies to recruit historically marginalized populations, and 54 studies (98.2%) lacked diversity recruitment goals. None of the trials discussed ethical considerations related to diverse recruitment. Conclusion This study highlights significant gaps in recruitment and retention strategies for historically marginalized populations in CRC clinical trials. Few studies implement strategies to address these disparities which affect the diversity of the trial population, underscoring the need for targeted efforts to improve trial inclusivity. Addressing these gaps is critical to ensuring more equitable and representative outcomes in CRC research.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (6) , e200211
Inequities in Epilepsy
Objectives The objective of this study was to complete a scoping review of current literature surrounding health inequities in epilepsy while providing recommendations for future research. Methods During July 2022, we searched MEDLINE and Ovid Embase to find published articles pertaining to epilepsy and health inequities. Initially, authors received training. Authors then screened, and data were extracted in a masked duplicate manner. Studies published within the time frame of 2011–2021 in all countries were deemed appropriate. We screened 5,325 studies for titles and abstracts and then 56 studies for full text. We evaluated the inequities of race/ethnicity, sex or gender, income, occupation status, education level, under-resourced/rural population, and LGBTQ+. To summarize the data and descriptive statistics of our study, we used Stata 17.0 (StataCorp, LLC, College Station, TX). Results We obtained a sample size of 45 studies for study inclusion. The most reported health inequities were income (18/45, 40.0%), under-resourced/rural population (15/45, 33.3%), and race/ethnicity (15/45, 33.3%). The least reported health inequity was LGBTQ+ (0/45, 0.0%). Discussion The findings of our study suggest that gaps exist in literature concerning epilepsy and inequities. The inequities of income status, under-resourced/rural population, and race/ethnicity were examined the most, while LGBTQ+, occupation status, and sex or gender were examined the least. With the ultimate goal of more equitable and patient-centered care in mind, it is vital that future studies endeavor to fill in these determined gaps.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (6) , e200211
Inequities in Epilepsy
Objectives The objective of this study was to complete a scoping review of current literature surrounding health inequities in epilepsy while providing recommendations for future research. Methods During July 2022, we searched MEDLINE and Ovid Embase to find published articles pertaining to epilepsy and health inequities. Initially, authors received training. Authors then screened, and data were extracted in a masked duplicate manner. Studies published within the time frame of 2011–2021 in all countries were deemed appropriate. We screened 5,325 studies for titles and abstracts and then 56 studies for full text. We evaluated the inequities of race/ethnicity, sex or gender, income, occupation status, education level, under-resourced/rural population, and LGBTQ+. To summarize the data and descriptive statistics of our study, we used Stata 17.0 (StataCorp, LLC, College Station, TX). Results We obtained a sample size of 45 studies for study inclusion. The most reported health inequities were income (18/45, 40.0%), under-resourced/rural population (15/45, 33.3%), and race/ethnicity (15/45, 33.3%). The least reported health inequity was LGBTQ+ (0/45, 0.0%). Discussion The findings of our study suggest that gaps exist in literature concerning epilepsy and inequities. The inequities of income status, under-resourced/rural population, and race/ethnicity were examined the most, while LGBTQ+, occupation status, and sex or gender were examined the least. With the ultimate goal of more equitable and patient-centered care in mind, it is vital that future studies endeavor to fill in these determined gaps.
Obesity, stigma, and person‐centered language: A serial cross‐sectional analysis of scientific literature
Objective: Language can influence societal perceptions of medical conditions. The employment of person‐centered language (PCL) in health care is reflected in many scientific publications; however, the extent of this adaptation in reference to obesity is unknown.Methods: This cross‐sectional analysis included a systematic search of PubMed obesity‐related articles across four cohorts spanning January 2004 through December 2006; January 2008 through December 2010; January 2015 through December 2018; and January 2019 through May 2020, respectively. Approximately 1971 publications were screened and examined for prespecified, non‐PCL terminology set forth by the American Medical Association Manual of Style and the International Committee of Medical Journal Editors, of which 991 were retained. Statistical analysis demonstrating PCL and non‐PCL findings was then performed. Incidence rates and cohort classifications were reported.Results: Of the 991 articles examined, it was found that 24.02% of publications adhered to PCL. Similar adherence was observed across obesity‐specific, general medicine, and nutrition journals. PCL adherence increased over time. The most common non‐PCL label was “obese,” occurring in 75.48% of articles.Conclusions: This investigation showed that non‐PCL in reference to obesity is widely evident in weight‐focused journals despite recommendations for adherence to PCL guidelines. Continued use of non‐PCL in reference to obesity in research may inadvertently perpetuate weight‐based stigma and health disparities in future generations.
Obesity, stigma, and person‐centered language: A serial cross‐sectional analysis of scientific literature
Objective: Language can influence societal perceptions of medical conditions. The employment of person‐centered language (PCL) in health care is reflected in many scientific publications; however, the extent of this adaptation in reference to obesity is unknown.Methods: This cross‐sectional analysis included a systematic search of PubMed obesity‐related articles across four cohorts spanning January 2004 through December 2006; January 2008 through December 2010; January 2015 through December 2018; and January 2019 through May 2020, respectively. Approximately 1971 publications were screened and examined for prespecified, non‐PCL terminology set forth by the American Medical Association Manual of Style and the International Committee of Medical Journal Editors, of which 991 were retained. Statistical analysis demonstrating PCL and non‐PCL findings was then performed. Incidence rates and cohort classifications were reported.Results: Of the 991 articles examined, it was found that 24.02% of publications adhered to PCL. Similar adherence was observed across obesity‐specific, general medicine, and nutrition journals. PCL adherence increased over time. The most common non‐PCL label was “obese,” occurring in 75.48% of articles.Conclusions: This investigation showed that non‐PCL in reference to obesity is widely evident in weight‐focused journals despite recommendations for adherence to PCL guidelines. Continued use of non‐PCL in reference to obesity in research may inadvertently perpetuate weight‐based stigma and health disparities in future generations.
- 10 January 2023
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 85-95
Assessing the Reporting of Harms in Systematic Reviews Focused on the Therapeutic and Cosmetic Uses of Botulinum Toxin
Background and Objective The expanding use of botulinum toxin (BoNT) in medical practice demonstrates the need to highlight whether there is adequate information regarding its safety profile. The aim of our study was to identify completeness of harms reporting for BoNT treatment within systematic reviews (SRs), assess quality of SRs using the AMSTAR-2 tool, and determine the degree of overlap among primary studies within each SR. Methods On May 31, 2022, we searched Embase, Epistemonikos, MEDLINE, and the Cochrane Database of Systematic Reviews for SRs on BoNT therapy. Screening and data extraction were performed in a masked, duplicate fashion. AMSTAR-2 was used to evaluate the methodological quality of included SRs. Corrected covered area (CCA) was calculated for SR dyads. Results Of the 90 included SRs, we found that 70 completed less than 50% of harms items. The most reported items were BoNT as a favorable intervention (73/90, 81.1%) and harms as a primary outcome (72/90, 80.0%). The least reported items were grades and severity scales used to classify harms (8/90, 8.9%) and number of treatment discontinuations in each arm (10/90, 11.1%). Eighty-three SRs were rated “critically low” (83/90, 92.2%), while 5 SRs were rated “high” (5/90, 5.6%) via AMSTAR-2 tool. Significant associations were found between completion of harms reporting and: (1) a “critically low” appraisal on AMSTAR-2 tool (p = 0.0060) and (2) whether harms was reported as a primary outcome (p = 0.0001). The total CCA overlap was determined to be 0.8%. Conclusion Our results demonstrate that harms are underreported within BoNT SRs. Because healthcare professionals often refer to SRs to guide clinical decision making, it is important to continue to explore shortcomings among BoNT literature in future studies.
- 10 January 2023
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 85-95
Assessing the Reporting of Harms in Systematic Reviews Focused on the Therapeutic and Cosmetic Uses of Botulinum Toxin
Background and Objective The expanding use of botulinum toxin (BoNT) in medical practice demonstrates the need to highlight whether there is adequate information regarding its safety profile. The aim of our study was to identify completeness of harms reporting for BoNT treatment within systematic reviews (SRs), assess quality of SRs using the AMSTAR-2 tool, and determine the degree of overlap among primary studies within each SR. Methods On May 31, 2022, we searched Embase, Epistemonikos, MEDLINE, and the Cochrane Database of Systematic Reviews for SRs on BoNT therapy. Screening and data extraction were performed in a masked, duplicate fashion. AMSTAR-2 was used to evaluate the methodological quality of included SRs. Corrected covered area (CCA) was calculated for SR dyads. Results Of the 90 included SRs, we found that 70 completed less than 50% of harms items. The most reported items were BoNT as a favorable intervention (73/90, 81.1%) and harms as a primary outcome (72/90, 80.0%). The least reported items were grades and severity scales used to classify harms (8/90, 8.9%) and number of treatment discontinuations in each arm (10/90, 11.1%). Eighty-three SRs were rated “critically low” (83/90, 92.2%), while 5 SRs were rated “high” (5/90, 5.6%) via AMSTAR-2 tool. Significant associations were found between completion of harms reporting and: (1) a “critically low” appraisal on AMSTAR-2 tool (p = 0.0060) and (2) whether harms was reported as a primary outcome (p = 0.0001). The total CCA overlap was determined to be 0.8%. Conclusion Our results demonstrate that harms are underreported within BoNT SRs. Because healthcare professionals often refer to SRs to guide clinical decision making, it is important to continue to explore shortcomings among BoNT literature in future studies.